

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 3.2

Revised – December 9, 2016.

| Controlled Therapeutic Medication | Threshold | Withdrawal Guideline | Dosing Specifications | Reference Notes | Note |
|-----------------------------------|--|----------------------|--|--|---|
| Acepromazine | 10 nanograms per milliliter as 2-(1-hydroxyethyl) promazine sulfoxide (HEPS) in urine | 48 hours | Single intravenous dose of acepromazine at 0.05 milligrams per kilogram | University of California at Davis project | Applicable analyte is metabolite HEPS |
| Albuterol | 1 nanogram per milliliter of urine | 72 hours | 720 micrograms total dose intra-nasal only ¹ . Based upon dosing up to 4 times per day | European Horseracing Scientific Liaison Committee Data | See Endnote |
| Betamethasone | 10 picograms per milliliter of plasma or serum | 7 days | Intra-articular administration of 9 milligrams of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP (American Regent product #0517-0720-01) ² | RMTC study | Intra-articular dosing only - applicable analyte is betamethasone in plasma or serum |
| Butorphanol | 300 nanograms per milliliter of total butorphanol in urine or 2 nanograms of free butorphanol per milliliter per milliliter of plasma or serum | 48 hours | Single intravenous dose of butorphanol as Torbugesic® (butorphanol tartrate) at 0.1 milligrams per kilogram | <i>Journal of Veterinary Pharmacology and Therapeutics</i> doi: 10.1111/j.1365-2885.2012.01385.x | Applicable analytes are total butorphanol (drug and conjugates) in urine and butorphanol in plasma (the drug itself, not any conjugate) |

¹ Administration of albuterol by any means other than intra-nasally has a high likelihood in resulting in a positive finding. This specifically includes oral administration. Trainers and veterinarians are cautioned against using oral albuterol

² Intramuscular administration of betamethasone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

| Controlled Therapeutic Medication | Threshold | Withdrawal Guideline | Dosing Specifications | Reference Notes | Note |
|-----------------------------------|---|----------------------|--|---|---|
| Cetirizine | 6 nanograms per milliliter of plasma or serum | 48 hours | 0.4 milligrams per kilogram twice daily for 5 doses | Kentucky Equine Drug Research Council/University of California at Davis study | Do not administer ivermectin within 48 hours of a race if the horse has been administered cetirizine. |
| Cimetidine | 400 nanograms per milliliter of plasma or serum | 24 hours | 20 milligrams per kilogram twice daily for 7 doses | Kentucky Equine Drug Research Council/University of California at Davis study | |
| Clenbuterol | 140 picograms per milliliter of urine or Level of Detection in plasma or serum | 14 days | Oral administration of clenbuterol as Ventipulmin [®] syrup (Boehringer-Ingelheim Vetmedica Inc., NADA 140-973) at 0.8 mcg/kg twice a day | University of California at Davis; Boehringer-Ingelheim Vetmedica, Inc. | Applicable analyte is clenbuterol |
| Dantrolene | 100 picograms per milliliter of 5-hydroxydantrolene in plasma or serum | 48 hours | Oral administration of 500 milligrams of dantrolene as paste (compounding pharmacy) or capsule formulation (Proctor and Gamble) | <i>Journal of Veterinary Pharmacology and Therapeutics</i> 34, 238-246 | |
| Detomidine | 2 nanograms per milliliter of carboxydetomidine in urine or 1 nanogram per milliliter of detomidine in blood. | 48 hours | 5 mg IV (once) | KY EDRG, UC Davis/UF Study. | Dormosedan [™] used in study. |

| Controlled Therapeutic Medication | Threshold | Withdrawal Guideline | Dosing Specifications | Reference Notes | Note |
|-----------------------------------|---|----------------------|---|--|--|
| Dexamethasone | 5 picograms per milliliter of plasma or serum | 72 hours | Intramuscular and intravenous administration of dexamethasone sodium phosphate or oral administration of dexamethasone at 0.05milligrams per kilogram regardless of route | RMTC study | Applicable analyte is dexamethasone in plasma or serum |
| Diclofenac | 5 nanograms per milliliter of plasma or serum | 48 hours | Five inch ribbon topical application of 1% diclofenac liposomal cream formulation. (Surpass Topical Anti-Inflammatory Cream, IDEXX Pharmaceuticals) | <i>Veterinary Therapeutics</i> 6: 57-66 (2005) | Applicable analyte is diclofenac in plasma or serum |
| Dimethyl sulfoxide (DMSO) | 10 micrograms per milliliter of plasma or serum | 48 hours | Intravenous | ARCI model rule | Applicable analyte is DMSO in plasma or serum |
| Firocoxib | 20 nanograms per milliliter of plasma or serum | 14 days | Oral administration of firocoxib as EQUIOXX oral paste at a daily dose of 0.1 milligram per kilogram for four days | RMTC study | Applicable analyte is firocoxib in plasma or serum |

| Controlled Therapeutic Medication | Threshold | Withdrawal Guideline | Dosing Specifications | Reference Notes | Note |
|-----------------------------------|---|----------------------|--|--|--|
| Furosemide | 100 nanogram per milliliter of plasma or serum | 4 hours | Single Intravenous dose of furosemide up to 500 milligram ³ | ARCI model rule | Must also have urine specific gravity < 1.010 for a violation. |
| Glycopyrrolate | 3 picograms per milliliter plasma or serum | 48 hours | Single intravenous dose of 1 milligram of glycopyrrolate as Glycopyrrolate Injection, USP (American Regent product # 0517-4601-25) | RMTC study; <i>Journal of Veterinary Pharmacology and Therapeutics</i> doi: 10.1111/j.1365-2885.2011.01272.x | Applicable analyte is glycopyrrolate in plasma or serum |
| Guaifenesin | 12 nanograms per milliliter of plasma or serum | 48 hours | 2 grams twice daily for 5 doses | Kentucky Equine Drug Research Council/University of California at Davis study | |
| Isoflupredone | 100 picograms per milliliter of plasma or serum | 7 days | 10 milligrams total dose subcutaneous or 20 milligrams total dose in one articular space | RMTC Study | |
| Lidocaine | 20 picograms per milliliter of total 30H-lidocaine in plasma or serum | 72 hours | 200 milligrams of lidocaine as its hydrochloride salt administered subcutaneously | European Horseracing Scientific Liaison Committee data; Iowa State University study. | Applies to total major hydroxylated metabolite (i.e., includes conjugates) |

³ ARCI-011-020(F)(2)(d) and ARCI-025-020(F)(2)(d) state that the dose of Furosemide “shall not exceed 500 milligrams nor be less than 150 milligrams”.

| Controlled Therapeutic Medication | Threshold | Withdrawal Guideline | Dosing Specifications | Reference Notes | Note |
|-----------------------------------|---|---------------------------|--|--|--|
| Mepivacaine | 10 nanograms total hydroxymepivacaine per milliliter of urine or above Level of Detection of mepivacaine in plasma or serum | 72 hours | Single 0.07 milligrams per kilogram subcutaneous dose of mepivacaine | European Horseracing Scientific Liaison Committee data | |
| Methocarbamol | 1 nanogram per milliliter of plasma or serum | 48 hours | Single intravenous dose of 15 milligrams per kilogram methocarbamol as Robaxin [®] or 5 grams orally | <i>Journal of Veterinary Pharmacology and Therapeutics</i> doi: 10.1111/jvp.12068 | Applicable analyte is methocarbamol in plasma or serum |
| Methylprednisolone | 100 picograms per milliliter of plasma or serum | See Dosing Specifications | Total dose of methylprednisolone acetate suspension in one articular space. ⁴ The recommended withdrawal for methylprednisolone acetate is a minimum of 21 days at a 100 milligram dose | <i>Journal of Veterinary Pharmacology and Therapeutics</i> volume 37, Issue 2, pages 125-132, April 2014 | Applicable analyte is methylprednisolone |
| Omeprazole | omeprazole sulfide - 10 nanograms per milliliter of plasma or serum | 24 hours | Orally (2.2 grams) once daily for 4 doses | Kentucky Equine Drug Research Council/University of California at Davis study | GastroGuard [™] used in the study |

⁴ Intramuscular administration of methylprednisolone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period. Please see Dosing Specifications for recommended withdrawal time.

| Controlled Therapeutic Medication | Threshold | Withdrawal Guideline | Dosing Specifications | Reference Notes | Note |
|--|---|-------------------------|---|---|--|
| Prednisolone | 1 nanogram per milliliter of plasma or serum | 48 hours | 1 milligram per kilogram orally | | Applicable analyte is prednisolone in plasma or serum |
| Procaine penicillin (administration must be reported to Commission) | 25 nanograms per milliliter of plasma or serum | Following entry to race | Intramuscular | RMTC – reference notes online | Mandatory surveillance of horse at owner's expense 6 hours before racing |
| Ranitidine | 40 nanograms per milliliter of plasma or serum | 24 hours | 8 milligrams per kilogram twice daily for 7 doses | Kentucky Equine Drug Research Council/University of California at Davis study | |
| Triamcinolone acetonide | 100 picograms per milliliter of plasma or serum | 7 days | Total dose of 9 milligram in one articular space ⁵ | <i>Equine Veterinary Journal</i> , 10.1111/evj.12059 (2013) | Applicable analyte is triamcinolone acetonide in plasma or serum |
| Xylazine | 200 picograms per milliliter of plasma or serum | 48 hours | 200 milligrams intravenously | University of California at Davis study | Applicable analyte is xylazine. |

⁵ Intramuscular administration of triamcinolone acetonide will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

Recent Document Revisions

| Date | Version | Revision | Revision Description |
|--------|---------|-----------------------------|---|
| Dec-16 | 3.2 | Omeprazole | Clarified threshold for omeprazole sulfide. |
| Sep-16 | 3.1 | Detomidine | Amended threshold and dosing specifications. |
| Mar-16 | 3 | Omeprazole | Amended threshold and dosing specifications |
| Mar-16 | 3 | Xylazine | Amended threshold and dosing specifications |
| Mar-16 | 3 | Guafenesin | Added as New Substance to Controlled Therapeutic Medication Schedule |
| Mar-16 | 3 | Cetirizine | Added as New Substance to Controlled Therapeutic Medication Schedule |
| Mar-16 | 3 | Ranitidine | Added as New Substance to Controlled Therapeutic Medication Schedule |
| Mar-16 | 3 | Cimetidine | Added as New Substance to Controlled Therapeutic Medication Schedule |
| Apr-15 | 2.02 | Methylprednisolone | Directed readers to use Dosing Specification column for recommended withdrawal guideline. |
| Apr-15 | 2.02 | Furosemide | Added clarifying language to Furosemide reflecting ARCI-011-020(F)(2)(d) and ARCI-025-020(F)(2)(d) minimum and maximum thresholds |
| Apr-15 | 2.02 | Added "For Horses" to Title | Added the words "for Horses" to document title |
| Apr-14 | 2.01 | Methocarbamol | Corrected dosage from 0.15 milligrams per kilogram to 15 milligrams per kilogram |
| Apr-14 | 2 | Dimethyl sulfoxide (DMSO) | Removed "oral" from dosing specifications |
| Apr-14 | 2 | Xylazine | Changed Note section from "Applies to xylazine and xylazine metabolite" to "Applies to analyte xylazine" |

| | | | |
|--------|---|--------------------------------------|--|
| Apr-14 | 2 | Xylazine | Corrected typographical error in Threshold from "0.01ng/mg of plasma or serum" to "0.01 nanogram per milliliter of plasma or serum" |
| Apr-14 | 2 | Isoflupredone | Added Isoflupredone as New Substance to Controlled Therapeutic Medication Schedule |
| Apr-14 | 2 | Albuterol | Added Albuterol as New Substance to Controlled Therapeutic Medication Schedule |
| Apr-14 | 2 | Flunixin, Ketoprofen, Phenylbutazone | Added Secondary Anti-Stacking Threshold |
| Apr-14 | 2 | Flunixin, Ketoprofen, Phenylbutazone | Created separate section for Non-Steroidal Anti-Inflammatory Drugs at end of Controlled Therapeutic Medication Schedule, Relocated Flunixin, Ketoprofen, and Phenylbutazone to new section |
| Apr-14 | 2 | <All Substances> | Changed Table Header from "No Pre-Race Treatment Within" to "Withdrawal Guideline" |
| Apr-13 | 1 | <All Substances> | Original Controlled Therapeutic Medication Schedule Adopted by ARCI Board of Directors |